Solid Biosciences Inc.

Contributing Author

Recent Articles by Solid Biosciences Inc.

Mar-19	Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates SLDB GlobeNewswire
Mar-11	Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial SLDB -5.68% GlobeNewswire
Mar-06	Solid Biosciences Announces Oversubscribed $240 Million Private Placement SLDB +20.32% GlobeNewswire
Mar-06	Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference SLDB +20.32% GlobeNewswire
Mar-02	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SLDB GlobeNewswire
Feb-09	Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy SLDB +5.21% GlobeNewswire
Feb-06	Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 SLDB GlobeNewswire
Jan-13	Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 SLDB +12.60% SLDB GlobeNewswire
Jan-12	Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia SLDB GlobeNewswire
Jan-12	Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia SLDB GlobeNewswire
Jan-06	Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference SLDB GlobeNewswire
Jan-05	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SLDB GlobeNewswire
Dec-16	Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services SLDB -7.56% SLDB GlobeNewswire
Dec-08	Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum SLDB GlobeNewswire
Dec-01	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SLDB GlobeNewswire
Dec-01	Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia SLDB GlobeNewswire
Nov-17	Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 SLDB GlobeNewswire
Nov-11	Solid Biosciences to Participate at Upcoming Investor Conferences SLDB +9.16% GlobeNewswire
Nov-06	Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy SLDB +7.25% GlobeNewswire
Nov-04	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SLDB -15.29% SLDB -10.78% GlobeNewswire
Nov-03	Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions SLDB GlobeNewswire
Oct-30	Solid Biosciences to Participate at Upcoming Investor Conferences SLDB GlobeNewswire
Oct-01	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SLDB GlobeNewswire
Oct-01	Solid Biosciences to Present at Upcoming Scientific Meetings SLDB GlobeNewswire
Sep-25	Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting SLDB -5.13% GlobeNewswire
Sep-23	Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 SLDB GlobeNewswire
Aug-28	Solid Biosciences to Participate at Upcoming Investor Conferences SLDB GlobeNewswire
Aug-12	Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates SLDB +10.60% SLDB GlobeNewswire
Aug-01	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SLDB GlobeNewswire
Jul-23	Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) SLDB +8.51% GlobeNewswire
Jul-08	Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) SLDB +6.72% SLDB +5.34% GlobeNewswire
Jul-01	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SLDB +5.87% SLDB -5.54% GlobeNewswire
Jun-03	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SLDB GlobeNewswire
May-28	Solid Biosciences to Participate at the Jefferies Global Healthcare Conference SLDB +7.24% GlobeNewswire
May-15	Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates SLDB +6.95% SLDB GlobeNewswire
May-01	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SLDB +18.08% SLDB +10.27% GlobeNewswire

Solid Biosciences Inc.

Recent Articles by Solid Biosciences Inc.

Upgrade your FINVIZ experience